Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_4
2
40%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed480%
not_yet_recruiting120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_4

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

NCT07533565
not_yet_recruiting

Mirabegron in Patients With Age-Related Macular Degeneration

NCT07305298
completedphase_2

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
completedphase_1

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

NCT05992428
completedphase_4

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

NCT02468375

Clinical Trials (5)

Showing 5 of 5 trials
NCT07533565Phase 4

A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients

Completed
NCT07305298

Mirabegron in Patients With Age-Related Macular Degeneration

Not Yet Recruiting
NCT01950520Phase 2

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Completed
NCT05992428Phase 1

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Completed
NCT02468375Phase 4

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5